X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

What you should know about RSV

By Mike Ybarra  |    November 15, 2022
You are probably reading a lot about a surge of cases of respiratory viruses like respiratory syncytial virus (RSV), influenza (the flu) and SARS-CoV-2, which causes COVID-19. The triple threat of...   Read More

Word of the Month: Long COVID

By Mike Ybarra  |    October 19, 2022
What is Long COVID?   Read More

Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus

By Mike Ybarra  |    October 13, 2022
Our industry is at the forefront of fighting the annual influenza virus. I recently had the chance to connect with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus about...   Read More

Partnerships are driving global COVID-19 treatment access

By Megan Van Etten  |    September 22, 2022
Through the constant efforts of U.S. innovators and their global partners, COVID-19 treatments have continued to be distributed to patients around the world — changing the pandemic’s treatment...   Read More

ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies

By Megan Van Etten  |    July 15, 2022
Member states of the World Trade Organization (WTO) recently agreed to a waiver of intellectual property (IP) protections for COVID-19 vaccines as part of the Trade-Related Aspects of Intellectual...   Read More

New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year

By Megan Van Etten  |    February 24, 2022
Biopharmaceutical companies are working across the industry and around the world to meet the global demand for COVID-19 vaccines. Companies have continued to ramp up their efforts to source needed...   Read More

What you need to know about newly authorized COVID-19 antiviral treatments

By Richard Moscicki, M.D.  |    February 22, 2022
In December 2021, the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for the first two oral antivirals for the treatment of certain COVID-19 patients. These...   Read More

Guest Blog: COVID-19 vaccines are the key to keeping kids healthy

By Guest Contributor  |    February 16, 2022
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...   Read More

Global COVID-19 vaccination matters now and for the future

By Anne McDonald Pritchett, PhD  |    November 29, 2021
Recently, I joined a panel at the Aspen Security Forum to discuss how we can best get vaccines in arms around the globe as we fight COVID-19. As I noted during my remarks, the world is more...   Read More

Understanding breakthrough COVID-19 infections

By Richard Moscicki, M.D.  |    November 11, 2021
The biopharmaceutical industry continues to work around the clock to research, develop and manufacture vaccines and therapeutics to prevent and treat COVID-19. Already, we’ve made unprecedented...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates